Literature DB >> 21630269

MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.

Manuela Ferracin1, Massimo Pedriali, Angelo Veronese, Barbara Zagatti, Roberta Gafà, Eros Magri, Maria Lunardi, Gardenia Munerato, Giulia Querzoli, Iva Maestri, Linda Ulazzi, Italo Nenci, Carlo M Croce, Giovanni Lanza, Patrizia Querzoli, Massimo Negrini.   

Abstract

Cancer of unknown primary (CUP) represents a common and important clinical problem. There is evidence that most CUPs are metastases of carcinomas whose primary site cannot be recognized. Driven by the hypothesis that the knowledge of primary cancer could improve patient's prognosis, we investigated microRNA expression profiling as a tool for identifying the tissue of origin of metastases. We assessed microRNA expression from 101 formalin-fixed, paraffin-embedded (FFPE) samples from primary cancers and metastasis samples by using a microarray platform. Forty samples representing ten different cancer types were used for defining a cancer-type-specific microRNA signature, which was used for predicting primary sites of metastatic cancers. A 47-miRNA signature was identified and used to estimate tissue-of-origin probabilities for each sample. Overall, accuracy reached 100% for primary cancers and 78% for metastases in our cohort of samples. When the signature was applied to an independent published dataset of 170 samples, accuracy remained high: correct prediction was found within the first two options in 86% of the metastasis cases (first prediction was correct in 68% of cases). This signature was also applied to predict 16 CUPs. In this group, first predictions exhibited probabilities higher than 90% in most of the cases. These results establish that FFPE samples can be used to reveal the tissue of origin of metastatic cancers by using microRNA expression profiling and suggest that the approach, if applied, could provide strong indications for CUPs, whose correct diagnosis is presently undefined.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630269      PMCID: PMC4325368          DOI: 10.1002/path.2915

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  33 in total

1.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.

Authors:  A J van de Wouw; M L G Janssen-Heijnen; J W W Coebergh; H F P Hillen
Journal:  Eur J Cancer       Date:  2002-02       Impact factor: 9.162

Review 2.  Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin.

Authors:  Federico A Monzon; Tracie J Koen
Journal:  Arch Pathol Lab Med       Date:  2010-02       Impact factor: 5.534

Review 3.  Pathologic evaluation of unknown primary cancer.

Authors:  Karin A Oien
Journal:  Semin Oncol       Date:  2009-02       Impact factor: 4.929

Review 4.  Cancer of unknown primary site: missing primary or missing biology?

Authors:  George Pentheroudakis; Evangelos Briasoulis; Nicholas Pavlidis
Journal:  Oncologist       Date:  2007-04

5.  Cancer of unknown primary origin: a decade of experience in a community-based hospital.

Authors:  Jose M Pimiento; Desarom Teso; Alpin Malkan; Stanley J Dudrick; J Alexander Palesty
Journal:  Am J Surg       Date:  2007-12       Impact factor: 2.565

6.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 7.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

8.  Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.

Authors:  J L Abbruzzese; M C Abbruzzese; R Lenzi; K R Hess; M N Raber
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

Review 9.  miRNAs in human cancer.

Authors:  Thalia A Farazi; Jessica I Spitzer; Pavel Morozov; Thomas Tuschl
Journal:  J Pathol       Date:  2010-11-18       Impact factor: 7.996

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  52 in total

Review 1.  MicroRNA, nutrition, and cancer prevention.

Authors:  Sharon A Ross; Cindy D Davis
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

2.  Olea europaea leaf extract alters microRNA expression in human glioblastoma cells.

Authors:  Berrin Tunca; Gulcin Tezcan; Gulsah Cecener; Unal Egeli; Secil Ak; Hulusi Malyer; Gulendam Tumen; Ayhan Bilir
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-22       Impact factor: 4.553

Review 3.  Progress in refining the clinical management of cancer of unknown primary in the molecular era.

Authors:  Elie Rassy; Nicholas Pavlidis
Journal:  Nat Rev Clin Oncol       Date:  2020-04-29       Impact factor: 66.675

4.  Overcoming obstacles in microRNA delivery towards improved cancer therapy.

Authors:  Dikla Ben-Shushan; Ela Markovsky; Hadas Gibori; Galia Tiram; Anna Scomparin; Ronit Satchi-Fainaro
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

Review 5.  miRNA profiling of cancer.

Authors:  Gianpiero Di Leva; Carlo M Croce
Journal:  Curr Opin Genet Dev       Date:  2013-03-04       Impact factor: 5.578

Review 6.  Exploiting microRNAs As Cancer Therapeutics.

Authors:  Tamsin Robb; Glen Reid; Cherie Blenkiron
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 7.  MicroRNA aberrations: An emerging field for gallbladder cancer management.

Authors:  Vishal Chandra; Jong Joo Kim; Balraj Mittal; Rajani Rai
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

8.  Development and validation of a microRNA based diagnostic assay for primary tumor site classification of liver core biopsies.

Authors:  Katharina Perell; Martin Vincent; Ben Vainer; Bodil Laub Petersen; Birgitte Federspiel; Anne Kirstine Møller; Mette Madsen; Niels Richard Hansen; Lennart Friis-Hansen; Finn Cilius Nielsen; Gedske Daugaard
Journal:  Mol Oncol       Date:  2014-08-01       Impact factor: 6.603

Review 9.  Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Authors:  Antonella Chillemi; Gianluca Zaccarello; Valeria Quarona; Manuela Ferracin; Chiara Ghimenti; Massimo Massaia; Alberto L Horenstein; Fabio Malavasi
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

10.  Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways.

Authors:  Hye-Jung E Chun; Emilia L Lim; Alireza Heravi-Moussavi; Saeed Saberi; Karen L Mungall; Mikhail Bilenky; Annaick Carles; Kane Tse; Inna Shlafman; Kelsey Zhu; Jenny Q Qian; Diana L Palmquist; An He; William Long; Rodrigo Goya; Michelle Ng; Veronique G LeBlanc; Erin Pleasance; Nina Thiessen; Tina Wong; Eric Chuah; Yong-Jun Zhao; Jacquie E Schein; Daniela S Gerhard; Michael D Taylor; Andrew J Mungall; Richard A Moore; Yussanne Ma; Steven J M Jones; Elizabeth J Perlman; Martin Hirst; Marco A Marra
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.